Overview of Dr. Lebwohl
Dr. Mark Lebwohl is a dermatologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Beth Israel, Mount Sinai Hospital of Queens, New York Eye and Ear Infirmary of Mount Sinai, and Mount Sinai Brooklyn. He received his medical degree from Harvard Medical School and has been in practice 45 years. He is one of 53 doctors at Mount Sinai Brooklyn and one of 26 doctors at New York Eye and Ear Infirmary of Mount Sinai who specialize in Dermatology. He has more than 100 publications and over 500 citings.
Office
5 e 98 st
New York, NY 10029
Education & Training
- Icahn School of Medicine at Mount SinaiResidency, Dermatology, 1981 - 1983
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1978 - 1981
- Harvard Medical SchoolClass of 1978
Certifications & Licensure
- NY State Medical License 1980 - 2027
- American Board of Dermatology Dermatology
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Gold Medal American Academy of Dermatology, 2022
- Top MD Consumers Checkbook
- Whos Who in Medicine and Healthcare Marquis Whos Who
- Join now to see all
Clinical Trials
- LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) Start of enrollment: 2010 Sep 01
- Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE) Start of enrollment: 2012 Aug 01
- LEO 90100 in the Treatment of Psoriasis Vulgaris Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controll...Mark G Lebwohl, John Y Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk
Advances in Therapy. 2025-02-11 - Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.Joseph F Merola, Laura K Ferris, Jeffrey M Sobell, Howard Sofen, John Osborne
Dermatology and Therapy. 2025-02-07 - Management of Chronic Generalized Pustular Psoriasis: A Review and Expert Opinion.Boni Elewski, Mark G Lebwohl
Journal of Psoriasis and Psoriatic Arthritis. 2025-02-02
Press Mentions
- MoonLake Initiates Three New Clinical Trials and Further Expands the Portfolio of Indications for the Nanobody® SonelokimabJanuary 9th, 2025
- FDA Approves Celltrion's Stelara BiosimilarDecember 30th, 2024
- U.S. FDA Approves Celltrion's STEQEYMA® (Ustekinumab-Stba), a Biosimilar to STELARA® (Ustekinumab)December 18th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: